These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15279606)

  • 1. Inhibition of endotoxin response by synthetic TLR4 antagonists.
    Hawkins LD; Christ WJ; Rossignol DP
    Curr Top Med Chem; 2004; 4(11):1147-71. PubMed ID: 15279606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist.
    Mullarkey M; Rose JR; Bristol J; Kawata T; Kimura A; Kobayashi S; Przetak M; Chow J; Gusovsky F; Christ WJ; Rossignol DP
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1093-102. PubMed ID: 12604686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue.
    Rossignol DP; Lynn M
    J Endotoxin Res; 2002; 8(6):483-8. PubMed ID: 12697095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endotoxin recognition molecules MD-2 and toll-like receptor 4 as potential targets for therapeutic intervention of endotoxin shock.
    Miyake K
    Curr Drug Targets Inflamm Allergy; 2004 Sep; 3(3):291-7. PubMed ID: 15379597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E5531, a pure endotoxin antagonist of high potency.
    Christ WJ; Asano O; Robidoux AL; Perez M; Wang Y; Dubuc GR; Gavin WE; Hawkins LD; McGuinness PD; Mullarkey MA
    Science; 1995 Apr; 268(5207):80-3. PubMed ID: 7701344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers.
    Rossignol DP; Wong N; Noveck R; Lynn M
    Innate Immun; 2008 Dec; 14(6):383-94. PubMed ID: 19039062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of soluble form of recombinant extracellular TLR4 domain with MD-2 enables lipopolysaccharide binding and attenuates TLR4-mediated signaling.
    Hyakushima N; Mitsuzawa H; Nishitani C; Sano H; Kuronuma K; Konishi M; Himi T; Miyake K; Kuroki Y
    J Immunol; 2004 Dec; 173(11):6949-54. PubMed ID: 15557191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity.
    Hawkins LD; Ishizaka ST; McGuinness P; Zhang H; Gavin W; DeCosta B; Meng Z; Yang H; Mullarkey M; Young DW; Yang H; Rossignol DP; Nault A; Rose J; Przetak M; Chow JC; Gusovsky F
    J Pharmacol Exp Ther; 2002 Feb; 300(2):655-61. PubMed ID: 11805229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functionalized dendrimers as endotoxin sponges.
    Cromer JR; Wood SJ; Miller KA; Nguyen T; David SA
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1295-8. PubMed ID: 15713373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insight in LPS antagonist.
    Ianaro A; Tersigni M; D'Acquisto F
    Mini Rev Med Chem; 2009 Mar; 9(3):306-17. PubMed ID: 19275723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage effect of E5564, Toll-like receptor 4 antagonist on d-galactosamine and lipopolysaccharide-induced acute liver failure in rats.
    Kitazawa T; Tsujimoto T; Kawaratani H; Fukui H
    J Gastroenterol Hepatol; 2010 May; 25(5):1009-12. PubMed ID: 20546456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia.
    Lynn M; Rossignol DP; Wheeler JL; Kao RJ; Perdomo CA; Noveck R; Vargas R; D'Angelo T; Gotzkowsky S; McMahon FG
    J Infect Dis; 2003 Feb; 187(4):631-9. PubMed ID: 12599080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Advances in the development of neutralizing therapies for sepsis].
    Florencia Henning M; Garda H; Bakás L
    Medicina (B Aires); 2006; 66(3):263-73. PubMed ID: 16871917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide.
    Savov JD; Brass DM; Lawson BL; McElvania-Tekippe E; Walker JK; Schwartz DA
    Am J Physiol Lung Cell Mol Physiol; 2005 Aug; 289(2):L329-37. PubMed ID: 15833764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipopolysaccharides from Helicobacter pylori can act as antagonists for Toll-like receptor 4.
    Lepper PM; Triantafilou M; Schumann C; Schneider EM; Triantafilou K
    Cell Microbiol; 2005 Apr; 7(4):519-28. PubMed ID: 15760452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected].
    Lynn M; Wong YN; Wheeler JL; Kao RJ; Perdomo CA; Noveck R; Vargas R; D'Angelo T; Gotzkowsky S; McMahon FG; Wasan KM; Rossignol DP
    J Pharmacol Exp Ther; 2004 Jan; 308(1):175-81. PubMed ID: 14566003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of endotoxin neutralization by synthetic cationic compounds.
    Andrä J; Gutsmann T; Garidel P; Brandenburg K
    J Endotoxin Res; 2006; 12(5):261-77. PubMed ID: 17059690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of meningococcal LPS as a major monocyte activator in IL-10 depleted shock plasmas and CSF by blocking the CD14-TLR4 receptor complex.
    Bjerre A; Brusletto B; Øvstebø R; Joø GB; Kierulf P; Brandtzaeg P
    J Endotoxin Res; 2003; 9(3):155-63. PubMed ID: 12831456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14.
    Akashi S; Saitoh S; Wakabayashi Y; Kikuchi T; Takamura N; Nagai Y; Kusumoto Y; Fukase K; Kusumoto S; Adachi Y; Kosugi A; Miyake K
    J Exp Med; 2003 Oct; 198(7):1035-42. PubMed ID: 14517279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of toll-like receptor 4 and endotoxin responsiveness in mice during perinatal period.
    Harju K; Ojaniemi M; Rounioja S; Glumoff V; Paananen R; Vuolteenaho R; Hallman M
    Pediatr Res; 2005 May; 57(5 Pt 1):644-8. PubMed ID: 15718365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.